A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy

Summary

This study is a multicenter, randomized, controlled, open-label, Phase Ⅱ clinical study to evaluate the efficacy, safety, Pharmacokinetics characteristics, Pharmacodynamics effects, and immunogenicity of JMT601 in participants with primary membranous nephropathy. The study has two parts. Part one is dose escalation part, and Part two is dose expansion part.

Timeline

Start

2025-06-30

Primary completion

2027-04-01

Completion

2029-03-01

Drugs

Indications